The combination of CDK4 and MAPK/ERK pathway inhibitor therapy in Melanoma: defining melanoma cell intrinsic and immune mediated responses

CDK4 和 MAPK/ERK 通路抑制剂联合治疗黑色素瘤：定义黑色素瘤细胞内在和免疫介导的反应

• 批准号: nhmrc : GNT1100189
• 负责人: Dr Carleen Cullinane
• 金额: $ 82.43万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/combination-cdk4-mapkerk-mediated-responses/1346106
• 关键词: combination; CDK4; MAPK; ERK; pathway

Early-stage melanomas can often be cured with surgery, but more advanced melanomas are harder to treat because standard melanoma treatments do not induce long term disease control. Thus newer types of treatment are required to treat more advanced melanomas. Our proposal will use a drug that stops melanoma cells from growing and in combination with other drugs causes the cells to release factors that activate the immune system to eliminate the tumour.

早期黑色素瘤通常可以通过手术治愈，但更晚期的黑色素瘤更难治疗，因为标准的黑色素瘤治疗不会引起长期的疾病控制。因此，需要更新类型的治疗来治疗更晚期的黑色素瘤。我们的建议将使用一种药物，阻止黑色素瘤细胞生长，并与其他药物结合，使细胞释放激活免疫系统的因子，以消除肿瘤。